QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT) (NCT05488470) | Clinical Trial Compass
CompletedNot Applicable
QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
United States22 participantsStarted 2023-02-20
Plain-language summary
The LINQ QT Study is a prospective, non-randomized, multi-center, observational, post-market clinical study investigating QT interval changes due to antiarrhythmic drug loading.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients implanted with LINQ/LINQII prior to the study enrollment (no more than 50% patients implanted with LINQII), but no greater than 2.5 years for LINQ or 3.5 years for LINQII, or patients who are indicated to receive a LINQ/LINQII implant at least 7 days prior to antiarrhythmic drug loading
* Patients who are scheduled to receive antiarrhythmic drug loading
* Age 18-80
* Patient is willing and able to comply with the protocol, including follow-up visits, and performing Holter recordings and patient activation transmissions
Exclusion Criteria:
* Patients who have a contraindication to long-term antiarrhythmic therapy
* Patients not suitable for long-term antiarrhythmic therapy
* Patients with a previous, existing cardiac implantation (i.e., cardiac pacemaker or cardiac resynchronization requiring \> 40% pacing, implantable cardioverter defibrillator (ICDs))
* Patients with permanent and persistent AF
* Co-enrollment in another study or planning to participate in a concurrent device study during the course of this clinical study that could confound the results
What they're measuring
1
QT Intervals During Antiarrhythmic Loading Hospitalization
Timeframe: Assessed in the 2-hr period after each of the first four doses, difference between the maximum and minimum QTc interval reported